High proliferation is associated with inferior outcome in male breast cancer patients

[1]  Jack Cuzick,et al.  Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study , 2012, Breast Cancer Research.

[2]  M. Ringnér,et al.  Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker , 2012, Breast Cancer Research.

[3]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[4]  K. Czene,et al.  Incidence and outcome of male breast cancer: an international population-based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Hedenfalk,et al.  Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden) , 2011, Acta oncologica.

[6]  M. Ringnér,et al.  High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer , 2011, Breast Cancer Research and Treatment.

[7]  M. Gariboldi,et al.  Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer , 2011, Breast Cancer Research and Treatment.

[8]  F. Morabito,et al.  Prognostic Value of Estrogen Receptor and Ki-67 Index after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Expressing High Levels of Proliferation at Diagnosis , 2011, Oncology.

[9]  K. Jirström,et al.  Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. , 2010, The American journal of pathology.

[10]  L. Holmberg,et al.  Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population‐based lymph node negative breast cancer cohort , 2010, International journal of cancer.

[11]  F. Penault-Llorca,et al.  Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. , 2010, Critical reviews in oncology/hematology.

[12]  R. Kanthan,et al.  Expression of cell cycle proteins in male breast carcinoma , 2010, World journal of surgical oncology.

[13]  L. Holmberg,et al.  Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[14]  Yrjö Collan,et al.  Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors , 2009, BMC Research Notes.

[15]  Gordon B Mills,et al.  Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer , 2009, Clinical Cancer Research.

[16]  K. Czene,et al.  Erratum to “How to treat male breast cancer” [The Breast 16S2 (2007) S147–S154] , 2008 .

[17]  R. Greil,et al.  Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.

[18]  H. Nevanlinna,et al.  Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer , 2008, Breast Cancer Research and Treatment.

[19]  H. Nevanlinna,et al.  Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values? , 2007, Histopathology.

[20]  B. Jonas,et al.  How to treat male breast cancer. , 2007 .

[21]  H. Nevanlinna,et al.  Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides , 2006, British Journal of Cancer.

[22]  G. Hortobagyi,et al.  Male breast cancer , 1998, The Lancet.

[23]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  G. Hortobagyi,et al.  Breast carcinoma in men , 2004, Cancer.

[25]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[26]  T. Hwang,et al.  Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients , 2003, Pathology international.

[27]  J. Wang-Rodriguez,et al.  Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with Treatment and Survival, a Study of 65 Cases , 2002, Modern Pathology.

[28]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[29]  J. Lamb,et al.  Regulation of the Functional Interaction between Cyclin D1 and the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[30]  J. Donohue,et al.  Molecular markers in male breast carcinoma , 1998, Cancer.

[31]  M. Ewen,et al.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.

[32]  J. Hurlimann,et al.  Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. , 1996, European journal of cancer.

[33]  L. Chiusa,et al.  Proliferative activity is a significant prognostic factor in male breast carcinoma. , 1994, The American journal of pathology.